Skip to main content
All lobbying filings

Fresenius Kabi USA LLC

Fresenius Kabi USA LLC filed a Q3 amendment for Fresenius Kabi USA LLC on November 25, 2025.

Lobbying for Fresenius Kabi USA LLC

As filed: FRESENIUS KABI USA LLC for FRESENIUS KABI USA LLC.

All filings by Fresenius Kabi USA LLC · Everything Fresenius Kabi USA LLC has reported

 Filing · LD-2 quarterly report Q3 amendment
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Nov 25, 2025
Expenses
$340,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Illinois

Official filing document

 Government bodies contacted 7

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 6
Trade (domestic/foreign)

Drug Shortages Domestic Manufacturing Tariffs

Medicare/Medicaid

Drug Shortages and Medicaid ERISA Fiduciary Duty IRA Reform

Health Issues

S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act S. 1414/H.R._: Expedited Access to Biosimilars Act S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 1041: Affordable Prescriptions for Patients Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 43: Skinny Labels, Big Savings Act S. 1097/H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 HR 4317: PBM Reform Act of 2025 HR 2214: DRUG Act S. 1553/H.R. 3160: PREVAIL Act S. 2305: Biosimilar Red Tape Elimination Act S. 2658: Medication Affordability and Patient Integrity Act ERISA Fiduciary Duty PTAB Discretionary Denials IRA Reform Human Factor Studies Interchangeability Biosimilar User Fee Act (BsUFA) Drug Shortages Domestic Manufacturing

Manufacturing

Domestic Manufacturing

Budget/Appropriations

Domestic Manufacturing Tariffs

Copyright/Patent/Trademark

PTAB Discretionary Denials

 Bills named in this filing 16
  • S. 1954
    Biosimilar Red Tape Elimination Act
  • H.R. 5526
    Biosimilar Red Tape Elimination Act
  • S. 1414
    Expedited Access to Biosimilars Act
  • S. 2276
    ETHIC Act
  • H.R. 3269
    ETHIC Act
  • S. 1041
    Affordable Prescriptions for Patients Act
  • S. 1096
    Preserve Access to Affordable Generics and Biosimilars Act
  • S. 43
    Skinny Labels, Big Savings Act
  • S. 1097
    Interagency Patent Coordination and Improvement Act of 2025
  • H.R. 4570
    Interagency Patent Coordination and Improvement Act of 2025
  • H.R. 4317
    PBM Reform Act of 2025
  • H.R. 2214
    DRUG Act
  • S. 1553
    PREVAIL Act
  • H.R. 3160
    PREVAIL Act
  • S. 2305
    Biosimilar Red Tape Elimination Act
  • S. 2658
    Medication Affordability and Patent Integrity Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem